Figure S1. Results of the sensitivity analysis according to different ACR response values obtained by Nash P. et al. (10)

A) ACR 20

B) ACR 50

Discount on ex-factory prices adalimumab

Necessary discount to apply to make cohort B more efficient than cohort A

Base case: 0% discount

Discount on ex-factory prices adalimumab

Necessary discount to apply to make cohort B more efficient than cohort A

Base case: 0% discount
Supplementary material

Figure S1. Results of the sensitivity analysis according to different ACR response values obtained by Nash P. et al. (10)

C) ACR 70

Difference in treatment cost (2 years) Discount on ex-factory prices adalimumab

Necessary discount to apply to make cohort B more efficient than cohort A

Base case: 0% discount -61,978 €
A) ACR 20

B) ACR 50

Figure S2. Results of the sensitivity analysis according to different ACR response values obtained by Strand V. et al. (11)
Supplementary material

Figure S2. Results of the sensitivity analysis according to different ACR response values obtained by Strand V. et al. (11)

C) ACR 70

![Graph showing the difference in treatment cost (2 years) with necessary discount to apply to make cohort B more efficient than cohort A. The base case is 0% discount, resulting in a cost of €43,305.]